BioWorld

Oct. 18, 2007

View Archived Issues

Studies Shine Light, Literally, On Neural Substrates Of Sleep

Read More

Cubist Gets Option To Acquire Illumigen; Funds HCV Drug

Cubist Pharmaceuticals Inc. moved to expand its pipeline beyond Cubicin (daptomycin for injection) by picking up an exclusive option to acquire Illumigen Biosciences Inc. (BioWorld Today) Read More

Pharmion's Amrubicin Begins Pivotal Trial In SCLC Patients

Read More

Osiris Targets GVHD, Crohn's With Stem Cell Therapy

Read More

Other News To Note

Read More

Financings Roundup

Read More

Clinic Roundup

Read More